Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 1/2 2Phase 2 1

Status

Completed 4Terminated 1

Sponsor Class

INDUSTRY 5NIH 1

Study Type

Interventional 5

Sponsor

Cancer Type

Gynecologic 5

Conditions

Ovarian Neoplasms 5Carcinoma, Non-Small-Cell Lung 5Multiple Myeloma 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Lymphoma, B-Cell 1Lymphoma 1Breast Neoplasms 1

Interventions

Paclitaxel 113Carboplatin 99Bevacizumab 59pembrolizumab 56liposomal doxorubicin 56Gemcitabine 42olaparib 39Topotecan 33niraparib 29Nivolumab 21Cisplatin 21Doxorubicin 17Cyclophosphamide 171-dodecylpyridoxal 16Drug Therapy 15Docetaxel 15avelumab 13Fulvestrant 11oregovomab 10Oxaliplatin 10rucaparib 9fludarabine 9Injections 9Fluorouracil 9veliparib 8mirvetuximab soravtansine 8atezolizumab 8Cetuximab 8fluzoparib 7cemiplimab 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
INDUSTRY × Ovarian Neoplasms × TER 286 × Clear all
NCT00350948 2013-11-27

ASSIST-5

Telik

Phase 3 Terminated
244 enrolled
Gynecologic

Ovarian Neoplasms

NCT00102973 2012-05-31

TLK286 (Telcyta) in Combination With Carboplatin (Paraplatin) Versus Doxil in Platinum Refractory or Resistant Ovarian Cancer

Telik

Phase 3 Completed
244 enrolled
Gynecologic

Ovarian Neoplasms

NCT00038428 2011-07-25

Phase 2 Study of TLK286 in Platinum Resistant Advanced Epithelial Ovarian Cancer

Telik

Phase 2 Completed
40 enrolled
Gynecologic

Ovarian Neoplasms

NCT00051948 2011-07-25

TLK286 in Combination With Paraplatin (Carboplatin) in Recurrent Ovarian Cancer

Telik

Phase 1/2 Completed
28 enrolled
Gynecologic

Ovarian Neoplasms

NCT00052065 2011-07-25

TLK286 in Combination With Doxil in Platinum Refractory or Resistant Ovarian Cancer

Telik

Phase 1/2 Completed
28 enrolled
Gynecologic

Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡